Abbott (NYSE:ABT) announced today that a study showed its TactiCath ablation catheter often led to more than a year of freedom from AFib symptoms.
The Persist-End study showed that 89% of patients treated for persistent AFib with the company’s TactiCath contact force ablation catheter, Sensor Enabled (TactiCath SE), remained symptom-free for up to 15 months after the procedure.